ASCO 2019 - American Society of Clinical Oncology Annual Meeting
May 31 - Jun 04, 2019 | ChicagoILUS
LARVOL is not affiliated with American Society of Clinical Oncology Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 1637 abstracts linked to Trials
Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment nave patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
SurVaxM with standard therapy in newly diagnosed glioblastoma: phase II trial update.
A Phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-nave metastatic castration-resistant prostate cancer.
Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.
Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).
A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.
A Phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lungcancer (NSCLC): A Phase II multicenter exploratory studyFinal data of patients who underwent surgical assessment.
A Phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).
Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors:A prospective patient-reported outcomes (PRO) analysis.
Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC).
Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.
Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110)- study.